Determinants of immunovirological response among children and adolescents living with HIV-1 in the Central Region of Cameroon

• Published in: Tropical medicine and infectious disease Vol. 9; no. 2; pp. 1 - 11
• Main Authors: Dobseu Soudebto, Rodolphe Steven, Fokam, Joseph, Kamgaing, Nelly, Fainguem, Nadine, Ngoufack Jagni Semengue, Ezechiel, Tommo Tchouaket, Michel Carlos, Kamgaing, Rachel, Nanfack, Aubin, Bouba, Yagai, Yimga, Junie, Chenwi Ambe, Collins, Gouissi, Hyacinthe, Efakika Gabisa, Jeremiah, Nnomo Zam, Krystel, Nka, Alex Durand, Sosso, Samuel Martin, Halle-Ekane, Gregory-Edie, Okomo, Marie-Claire, Ndjolo, Alexis
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland MDPI 01.02.2024; MDPI AG
• Subjects: Acquired immune deficiency syndrome; AIDS; Analysis; Cameroon; Data collection; Disease prevention; DNA polymerases; Drug resistance; Drug therapy; Ethylenediaminetetraacetic acid; Flow cytometry; Highly active antiretroviral therapy; HIV; HIV (Viruses); HIV infections; HIV patients; HIV-positive children; Human immunodeficiency virus; Immune system; immunological failure; Immunology; Infections; International organizations; Lymphocytes; paediatrics; Pediatrics; Plasma; Prevention; Protease inhibitors; Proteases; Teenagers; United States. National Commission on Acquired Immune Deficiency Syndrome; viral suppression; Cameroon; Sub-Saharan Africa; Africa; paediatrics; immunological failure; viral suppression; Cameroon; HIV
• ISSN: 2414-6366; 2414-6366
• DOI: 10.3390/tropicalmed9020048

About 90% of new HIV-1 infections in children occur in sub-Saharan Africa, where treatment monitoring remains suboptimal. We sought to ascertain factors associated with immunovirological responses among an ART-experienced paediatric population in Cameroon. A laboratory-based and analytical study was conducted from January 2017 throughout December 2020 wherein plasma viral load (PVL) analyses and CD4 cell counts were performed. Viral suppression (VS) was defined as PVL < 1000 copies/mL and immunological failure (IF) as CD4 < 500 cells/muL for participants <=5 years and CD4 < 250 cells/muL for those >5 years; p < 0.05 was considered statistically significant. Overall, 272 participants were enrolled (median age: 13 [9-15.5] years; 54% males); median ART duration 7 [3-10] years. Globally, VS was achieved in 54.41%. VS was 56.96% in urban versus 40.48% in rural areas (p equivalent 0.04). IF was 22.43%, with 15.79% among participants <=5 years and 22.92% among those >5 years (p equivalent 0.66). IF was 20.43% in urban versus 33.33% in rural areas (p equivalent 0.10). Following ART, IF was 25.82% on first-line (non-nucleoside reverse transcriptase inhibitors; NNRTI-based) versus 10.17% on second-line (protease inhibitor-based) regimens (p equivalent 0.01). Interestingly, IF was 7.43% among virally suppressed versus 40.32% among virally unsuppressed participants (p < 0.0001). A low VS indicates major challenges in achieving AIDS' elimination in this paediatric population, especially in rural settings and poor immune statuses. Scaling up NNRTI-sparing regimens alongside close monitoring would ensure optimal therapeutic outcomes.